PMID- 24999252
OWN - NLM
STAT- MEDLINE
DCOM- 20151215
LR  - 20220317
IS  - 1557-3117 (Electronic)
IS  - 1053-2498 (Linking)
VI  - 34
IP  - 3
DP  - 2015 Mar
TI  - Pulmonary hypertension related to left heart disease: insight from a wireless 
      implantable hemodynamic monitor.
PG  - 329-37
LID - S1053-2498(14)01112-7 [pii]
LID - 10.1016/j.healun.2014.04.014 [doi]
AB  - BACKGROUND: Pulmonary hypertension (PH) associated with left heart disease (World 
      Health Organization [WHO] Group II) has previously been linked with significant 
      morbidity and mortality. However, there are currently no approved therapies or 
      hemodynamic monitoring systems to improve outcomes in WHO Group II PH. METHODS: 
      We conducted a retrospective analysis of the CHAMPION trial of an implantable 
      hemodynamic monitor (IHM) in 550 New York Heart Association (NYHA) Functional 
      Class III HF patients, regardless of left ventricular ejection fraction (LVEF) or 
      heart failure (HF) etiology. We evaluated clinical variables, changes in medical 
      therapy, HF hospitalization rates and survival in patients with and without WHO 
      Group II PH. RESULTS: Data were obtained for 314 patients (59%) who had WHO Group 
      II PH. Patients without PH were at significantly lower risk for mortality than PH 
      patients (hazard ratio [HR] 0.31, 95% confidence interval [CI] 0.19 to 0.52, p < 
      0.0001). PH patients had higher HF hospitalization rates than non-PH patients 
      (0.77/year vs 0.37/year; HR 0.49, 95% CI 0.39 to 0.61, p < 0.001). In patients 
      with and without PH, ongoing knowledge of hemodynamic data resulted in a 
      reduction in HF hospitalization for PH patients (HR 0.64, 95% CI 0.51 to 0.81, p 
      = 0.002) and for non-PH patients (HR 0.60, 95% CI 0.41 to 0.89, p = 0.01). Among 
      PH patients, there was a reduction in the composite end-point of death and HF 
      hospitalization with ongoing knowledge of hemodynamics (HR 0.74, 95% CI 0.55 to 
      0.99, p = 0.04), but no difference in survival (HR 0.78, 95% CI 0.50 to 1.22, p = 
      0.28). CONCLUSIONS: WHO Group II PH is prevalent and identifies HF patients at 
      risk for adverse outcomes. Ongoing knowledge of hemodynamic variables may allow 
      for more effective treatment strategies to reduce the morbidity of this disease.
CI  - Copyright (c) 2015 International Society for Heart and Lung Transplantation. 
      Published by Elsevier Inc. All rights reserved.
FAU - Benza, Raymond L
AU  - Benza RL
AD  - Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, Pennsylvania. 
      Electronic address: rbenza@wpahs.org.
FAU - Raina, Amresh
AU  - Raina A
AD  - Cardiovascular Institute, Allegheny General Hospital, Pittsburgh, Pennsylvania.
FAU - Abraham, William T
AU  - Abraham WT
AD  - Division of Cardiovascular Medicine, The Ohio State University, Columbus, Ohio.
FAU - Adamson, Philip B
AU  - Adamson PB
AD  - Division of Cardiology, Oklahoma Foundation for Cardiovascular Research, Oklahoma 
      City, Oklahoma.
FAU - Lindenfeld, JoAnn
AU  - Lindenfeld J
AD  - Division of Cardiology, University of Colorado Health Sciences Center, Denver, 
      Colorado.
FAU - Miller, Alan B
AU  - Miller AB
AD  - Division of Cardiology, University of Florida, Jacksonville, Florida.
FAU - Bourge, Robert C
AU  - Bourge RC
AD  - Division of Cardiology, University of Alabama at Birmingham, Birmingham, Alabama.
FAU - Bauman, Jordan
AU  - Bauman J
AD  - CardioMEMS, Inc., Atlanta, Georgia.
FAU - Yadav, Jay
AU  - Yadav J
AD  - CardioMEMS, Inc., Atlanta, Georgia.
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Randomized Controlled Trial
DEP - 20140510
PL  - United States
TA  - J Heart Lung Transplant
JT  - The Journal of heart and lung transplantation : the official publication of the 
      International Society for Heart Transplantation
JID - 9102703
SB  - IM
CIN - J Heart Lung Transplant. 2015 Mar;34(3):310-1. PMID: 25240459
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Hypertension, Pulmonary/epidemiology/*etiology/physiopathology
MH  - Male
MH  - Middle Aged
MH  - Monitoring, Physiologic/*instrumentation
MH  - Morbidity/trends
MH  - *Prostheses and Implants
MH  - Retrospective Studies
MH  - Stroke Volume/*physiology
MH  - Survival Rate/trends
MH  - Telemetry/*instrumentation
MH  - Time Factors
MH  - United States/epidemiology
MH  - Ventricular Dysfunction, Left/*complications/diagnosis/physiopathology
MH  - Ventricular Function, Left/*physiology
OTO - NOTNLM
OT  - congestive heart failure
OT  - hemodynamics
OT  - hospitalizations
OT  - implantable monitors
OT  - mortality
OT  - pulmonary hypertensions
EDAT- 2014/07/08 06:00
MHDA- 2015/12/17 06:00
CRDT- 2014/07/08 06:00
PHST- 2014/02/11 00:00 [received]
PHST- 2014/04/24 00:00 [revised]
PHST- 2014/04/30 00:00 [accepted]
PHST- 2014/07/08 06:00 [entrez]
PHST- 2014/07/08 06:00 [pubmed]
PHST- 2015/12/17 06:00 [medline]
AID - S1053-2498(14)01112-7 [pii]
AID - 10.1016/j.healun.2014.04.014 [doi]
PST - ppublish
SO  - J Heart Lung Transplant. 2015 Mar;34(3):329-37. doi: 
      10.1016/j.healun.2014.04.014. Epub 2014 May 10.